title: Relationships between sirolimus dosing, concentration and outcomes in renal transplant recipients.
abstract: OBJECTIVE
  To explore relationships between sirolimus dosing, concentration and clinical outcomes.
  
  
  METHODS
  Data were collected from 25 kidney transplant recipients (14 M/11 F), median 278 days after transplantation. Outcomes of interest were white blood cell (WBC) count, platelet (PLT) count, and haematocrit (HCT). A naive pooled data analysis was performed with outcomes dichotomized (Mann-Whitney U-tests).
  
  
  RESULTS
  Several patients experienced at least one episode when WBC (n = 9), PLT (n = 12), or HCT (n = 21) fell below the lower limits of the normal range. WBC and HCT were significantly lower (P < 0.05) when sirolimus dose was greater than 10 mg day(-1), and sirolimus concentration greater than 12 microg l(-1). No relationship was shown for PLT and dichotomized sirolimus dose or concentration.
  
  
  CONCLUSIONS
  Given this relationship between sirolimus concentration and effect, linked population pharmacokinetic-pharmacodynamic modelling using data from more renal transplant recipients should now be used to quantify the time course of these relationships to optimize dosing and minimize risk of these adverse outcomes.
authors.affiliation: School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Dansirikul
authors.forename: S B
authors.initials: SB
authors.lastname: Duffull
authors.forename: R G
authors.initials: RG
authors.lastname: Morris
authors.forename: S E
authors.initials: SE
authors.lastname: Tett
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D006400:Hematocrit; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D007958:Leukocyte Count; D010976:Platelet Count; D011183:Postoperative Complications / Q000139:chemically induced*; D011379:Prognosis; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus